PegBio Co., Ltd. Class H (2565) Stock Price & Analysis
2565 Stock Chart & Stats
- Day’s Range
- HKD 3.16 - HKD 3.76
- 52-Week Range
- HKD 3.05 - HKD 77.00
- Previous Close
- HKD 3.37
- Volume
- N/A
- Average Volume (3M)
- 11.03M
- Market Cap
- HKD 1.68B
- Enterprise Value
- HKD 1.79B
- Total Cash (Recent Filing)
- N/A
- Total Debt (Recent Filing)
- N/A
- Price to Earnings (P/E)
- ―
- Beta
- 1.79
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
PegBio Co., Ltd. Class H News
PegBio Deepens Losses as Paidakang Commercialization and Metabolic Pipeline Gain Traction
An announcement from PegBio Co., Ltd. Class H ( ($HK:2565) ) is now available. PegBio Co., Ltd., a China-based biopharmaceutical developer of treatments for diabetes, obesity and metabolic diseases, is
PegBio’s Diabetes Drug Paidakang Enters Nationwide Clinical Use, Triggers Second Royalty Milestone
The latest announcement is out from PegBio Co., Ltd. Class H ( ($HK:2565) ). PegBio Co., Ltd., a China-based biopharmaceutical company, has independently developed Paidakang, a long-acting GLP-1 receptor agonist
2565 FAQ
What was PegBio Co., Ltd. Class H’s price range in the past 12 months?
What is PegBio Co., Ltd. Class H’s market cap?
When is PegBio Co., Ltd. Class H’s upcoming earnings report date?
How were PegBio Co., Ltd. Class H’s earnings last quarter?
Is PegBio Co., Ltd. Class H overvalued?
Does PegBio Co., Ltd. Class H pay dividends?
What is PegBio Co., Ltd. Class H’s EPS estimate?
How many shares outstanding does PegBio Co., Ltd. Class H have?
What happened to PegBio Co., Ltd. Class H’s price movement after its last earnings report?
Which hedge fund is a major shareholder of PegBio Co., Ltd. Class H?
What is the TipRanks Smart Score and how is it calculated?
PegBio Co., Ltd. Class H Stock Smart Score
Company Description
PegBio Co., Ltd. Class H
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company's PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 an Opioid receptor antagonist, which is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-line treatment of type 2 diabetes mellitus and obesity; and PB-722 that has completed the FDA orphan drug qualification certification for use in the treatment of congenital hyperinsulinemia. Additionally, the company is conducting preclinical studies test on PB-2301, a GLP-1/glucose-dependent insulinotropic polypeptide; and PB-2309, a GLP-1/GIP/ glucagon triple receptor agonist for the treatment of type 2 diabetes mellitus, NASH, and obesity. PegBio Co., Ltd. was incorporated in 2008 and is based in Hangzhou, China.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Min Xu
- Employees
- 58
- Website
- www.pegbio.com
- Address
- CN
PegBio Co., Ltd. Class H (2565) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 4 | 2 | 4 |
| Moving Averages | 2 | 0 | 10 |
